Johnson & Johnson (JNJ) is facing the first lawsuits in Britain over allegations that its talc products cause cancer, reported Reuters. KP Law said it filed the case at the English High Court on Tuesday against J&J and Kenvue UK Limited, a subsidiary of Kenvue (KVUE), on behalf of more than 3,000 people, the report noted. J&J referred queries to Kenvue, which it said “retained the responsibility and any purported liability for talc-related litigation outside of the United States and Canada” and Kenvue said in a statement that J&J baby powder “did not contain asbestos, and does not cause cancer,” Reuters added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson Stock (JNJ) Flattens as it Faces U.K. Talcum Powder Cancer Claims
- Johnson & Johnson’s Tecvayli regimen improves survival in multiple myeloma trial
- Why Dividend King Johnson & Johnson (JNJ) Excels in Volatile Markets
- 3 Best Dividend Aristocrat Stocks to Buy Now, 10/15/2025
- Johnson & Johnson price target raised to $210 from $185 at Argus
